A shortage listing ends. 20 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
December 2025 — Vol. 2, No. 12
Page 4 of 4 of this archive, newest first.
Also filed — page 4
the rolling newsroom, December 2025The online reseller trading as Adamant Research Supply enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
The United Kingdom health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
LEADER misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Inspectors cite the online reseller trading as Adamant Research Supply over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
TRIUMPH-1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
India pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
What changed at ERP in December, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Singapore caps exenatide prescribing to 11 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
REWIND misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Canada declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The quiet end of the relabeller trading as Vantris Bio
A proper account of an operation that existed, and of what closing it cost.
A shortage listing ends. 3 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
What a 21% rise in coupling-reagent prices does to a 5 mg vial
Follow the resin, not the catalogue.
PeptideMeter result on a Zhuhai tirzepatide lot lands 3.5 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.